Quince Therapeutics, Inc. QNCX
Set alert
At close · Oct 9
After hours · Oct 9, 4:00 PM ET
- YTD
- -95.26%
- 1 year
- -91.82%
- Open
- 30.50
- Prev close
- 29.36
- Mkt cap
- 8.83M
- Vol
- 138.74K
- Avg vol
- 31.09K
- EPS
- -156.71
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 29.84
- High
- 37.00
- Forward P/E
- -5.68
- Beta
- 0.71
- Short ratio
- 2.27
- Inst. own
- 25.53%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 13, 2024
- 50-d avg
- 1.59
- 200-d avg
- 1.03
- 1y target
- 9.00
2Y chart
Signals (9)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 28, 2026 | 5 days ago |
| SMA: Bullish | Oct 15, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 15, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 13, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 13, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 12, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 9, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 2, 2026 | 1 month ago |
| RSI: Overbought | Aug 21, 2026 | 2 months ago |
Key statistics
- Market cap
- 77.44M
- Enterprise value
- 37.16M
- Trailing P/E
- 0.00
- Forward P/E
- -5.68
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.89
- EPS (TTM)
- -1.24
- Beta
- 0.71
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -7.84M
- Total cash
- 59.45M
- Total debt
- 14.38M
- Return on equity
- -79.38%
- Shares outstanding
- 44.00M
- Short % of float
- 5.86%
- 50-day average
- 1.59
- 200-day average
- 1.03
Analyst view
Consensus: strong buy
- Target (low)
- 6.00
- Target (mean)
- 9.00
- Target (high)
- 12.00
- Strong buy1
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 13, 2024
Expected Aug 13, 2024. Consensus EPS estimate -0.10.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | 0.00 | -0.13 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | -0.18 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | 0.00 | -0.26 | — | — |
| Apr 1, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 18, 2024 | Brookline Capital | init | — | Buy |
| Nov 14, 2024 | D. Boral Capital | main | Buy | Buy |
| Nov 12, 2024 | D. Boral Capital | main | Buy | Buy |
| Nov 7, 2024 | Maxim Group | init | — | Buy |
| Oct 29, 2024 | Rodman & Renshaw | init | — | Buy |
| Oct 22, 2024 | EF Hutton | init | — | Buy |
About Quince Therapeutics, Inc.
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- quincetx.com
News
- Quince Therapeutics (NASDAQ: QNCX) renames itself IRulya and sets IRLA ticker
- Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease
- Raymond James Initiates Coverage On Quince Therapeutics with Outperform Rating, Announces Price Target of $72
- Quince Therapeutics Stockholders Approve PIPE, Share Increase and Equity Plans
- Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript
- Quince Therapeutics, Inc. (QNCX) Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and Bronchiolitis Obliterans Syndrome Transcript
- This Ares Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026
- Quince Therapeutics to Participate in September 2026 Investor Conferences
Your note
Sign in to keep a note on QNCX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| HANNAH BRENDAN | Chief Operating Officer | Purchase | Aug 20, 2024 | 296,540 |
| LAMOND DAVID A. | Director | Purchase | Dec 13, 2023 | 0 |
| MCLOUGHLIN MARGARET | Director | Purchase | Aug 7, 2023 | 8,000 |
| MONOHON TED | Officer | Sale | Mar 5, 2023 | 27,440 |
| RYAN CHARLES S | President | Purchase | Aug 19, 2024 | 122,461 |
| THYE DIRK | Chief Executive Officer | Purchase | Aug 29, 2024 | 843,941 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 2.73% | 1,199,648 | 2.11M | Sep 29, 2024 |
| EPIQ Capital Group, LLC | 1.88% | 825,942 | 1.45M | Sep 29, 2024 |
| Renaissance Technologies, LLC | 1.19% | 522,576 | 919.73K | Sep 29, 2024 |
| Almitas Capital LLC | 0.87% | 382,882 | 673.87K | Sep 29, 2024 |
| Blackrock Inc. | 0.81% | 358,358 | 630.71K | Sep 29, 2024 |
| HighTower Advisors, LLC | 0.78% | 341,570 | 601.16K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.93% | 847,959 | 1.49M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.79% | 345,527 | 608.13K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.43% | 188,294 | 331.40K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.20% | 86,317 | 151.92K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.18% | 78,157 | 137.56K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.12% | 55,000 | 96.80K | Sep 29, 2024 |